Short-Term Debt to Equity: Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX) is developing a portfolio of oncology and analgesic products, expanding its range through existing capacities and patent rights. This historical price chart on GURU.Markets, where the indicator stands at 0.00, links this growth to stable demand for postoperative care products and high margins on government contracts. Distribution optimization and the integration of the anesthetic Zynrelef into surgical practice are currently driving positive momentum.

Heron Therapeutics focuses on developing innovative non-opioid analgesics to replace opioids in postoperative therapy. The current short-term debt-to-equity ratio is 0.00, reflecting the proportion of liabilities maturing within one year relative to equity. An increase in this indicator may signal aggressive expansion financing; however, it exponentially raises liquidity risk during cash flow gaps. The stability of this metric confirms the business's financial resilience to short-term shocks.